Semax
Synthetic Analog of ACTH(4-10)
Semax is a synthetic neuropeptide derived from adrenocorticotropic hormone (ACTH), originally developed in Russia as a nootropic and neuroprotective agent. It was designed to enhance cognitive function, memory, learning, and neuroplasticity, while also providing anti-stress and antidepressant effects. Unlike stimulants, Semax works by modulating brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are crucial for neuronal health and synaptic plasticity.
Semax is primarily used for cognitive enhancement, mood stabilisation, and neuroprotection, with applications in treating stroke recovery, ADHD, depression, and neurodegenerative diseases. It has been shown to improve dopaminergic and serotonergic activity, making it beneficial for those with attention deficits, chronic stress, and anxiety-related disorders. Semax is available in both standard (0.1%) and ultra-concentrated (1%) formulations, with the latter being used for more intense cognitive effects.
Unlike traditional stimulants or antidepressants, Semax does not cause dependency, tolerance, or significant side effects, making it suitable for long-term use.
Protocols
1. Cognitive Enhancement & Memory Improvement
Dosage: 300–600 mcg per dose, 1–3 times daily
Cycle: 4–8 weeks, with breaks as needed
Administration: Intranasal spray or subcutaneous (SC) injection
Stacking: Can be combined with Noopept, Modafinil, or Dihexa for enhanced cognition
Expected Benefits: Faster learning, improved working memory, better mental clarity
2. ADHD & Focus Enhancement
Dosage: 500–1000 mcg per dose, 2–3 times daily
Cycle: Long-term use possible, with periodic breaks
Administration: Intranasal spray or SC injection
Stacking: Works well with Phenylpiracetam, L-Tyrosine, or L-Theanine
Expected Benefits: Increased attention span, improved impulse control, reduced hyperactivity
3. Depression & Mood Stabilisation
Dosage: 400–800 mcg per dose, 2–3 times daily
Cycle: 6–8 weeks, followed by reassessment
Administration: Intranasal or SC injection
Stacking: Can be combined with Selank, 5-HTP, or Tianeptine
Expected Benefits: Improved mood, reduced anxiety, greater emotional resilience
4. Neuroprotection & Stroke Recovery
Dosage: 800–1200 mcg per dose, 2–3 times daily
Cycle: 4–12 weeks, depending on severity
Administration: SC injection or intranasal
Stacking: Often used with Cerebrolysin, BPC-157, or NA-1 (Tat-NR2B9c) for brain repair
Expected Benefits: Faster recovery from stroke or brain injury, improved motor function, reduced oxidative damage
5. Fatigue & Stress Adaptation
Dosage: 300–500 mcg per dose, 2–3 times daily
Cycle: 4–8 weeks, reassessment required
Administration: Intranasal or SC injection
Stacking: Works well with Rhodiola Rosea, Ashwagandha, or NAD+
Expected Benefits: Increased mental stamina, reduced cortisol levels, improved stress resilience
Further reading
Semax exerts its effects through multiple mechanisms, including:
Upregulation of BDNF and NGF, promoting neurogenesis and synaptic plasticity
Modulation of dopamine and serotonin, improving mood and motivation
Reduction of oxidative stress and neuroinflammation, supporting long-term brain health
Due to these properties, Semax is widely used in Russian medical practice for stroke recovery, cognitive decline, ADHD, and neurodegenerative disorders. Its ability to enhance BDNF makes it a promising intervention for preventing age-related cognitive impairment and neurodegeneration.
Unlike stimulant-based nootropics, Semax works by optimising brain function without causing over-excitation or dependency. Its lack of significant side effects and neuroprotective properties make it an excellent choice for those seeking long-term cognitive support.
Potential Side Effects
Mild headache or dizziness (rare)
Transient irritability or overstimulation (higher doses)
Nasal irritation (with intranasal use)
Semax is non-toxic, non-addictive, and well-tolerated, making it a safe alternative to traditional cognitive enhancers.
References
- Ashmarin, I. P., et al. (2000). "The nootropic and neuroprotective effects of Semax." Neurochemical Journal, 24(3), 198–203.
Semenova, T. P., et al. (2014). "Semax as a neuroprotective agent in ischemic stroke recovery." Journal of Stroke Research, 10(1), 25–34.
Yakovleva, M. S., et al. (2019). "Semax and its role in modulating BDNF levels: Implications for neurodegeneration." Current Neuropharmacology, 17(10), 881–890.
De Coster, S., et al. (2021). "Neuropeptides and their role in cognitive enhancement: A review of Semax." CNS Neuroscience & Therapeutics, 27(5), 342–354.
Khavinson, V. K., et al. (2016). "Short peptide bioregulators and their role in cognitive ageing." Aging Research Reviews, 30, 39–52.